Aeglea BioTherapeutics, Inc. (AGLE)
Company Info
Highlights
$48.63M
-$74.15
$17.50
3.47%
3.68
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
AGLE
N/A
N/A
N/A
N/A
N/A
N/A
^GSPC (Benchmark)
-0.64%
8.97%
-2.62%
11.90%
15.76%
10.69%
Monthly Returns
The table below presents the monthly returns of AGLE, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 28.25% | 28.25% | |||||||||||
| 2023 | 11.14% | -21.60% | -26.02% | -41.83% | -23.00% | 246.81% | 25.44% | 1.75% | -14.78% | -4.98% | 60.31% | 15.33% | 91.33% |
| 2022 | -9.47% | -35.58% | -16.97% | -37.39% | 9.72% | -68.03% | -17.76% | 25.90% | 0.57% | 95.82% | -59.71% | 8.41% | -90.53% |
| 2021 | -11.69% | 7.19% | 6.31% | -1.77% | -15.04% | 5.30% | -11.93% | 18.27% | 9.66% | -7.92% | -14.75% | -23.88% | -39.64% |
| 2020 | -4.97% | -5.92% | -31.77% | 66.74% | 13.38% | 4.99% | -25.95% | 6.20% | -2.54% | 8.32% | 11.46% | -8.06% | 3.01% |
| 2019 | 22.03% | -8.53% | -3.71% | -14.91% | -8.91% | 9.78% | 30.80% | -12.89% | -1.47% | -1.04% | 12.35% | -10.64% | 2.00% |
| 2018 | 19.78% | 11.88% | 36.83% | -5.85% | 14.35% | -0.94% | -20.51% | 29.96% | -12.44% | -9.82% | -2.43% | -11.05% | 38.45% |
| 2017 | -8.28% | 55.39% | 20.16% | -4.03% | -40.98% | -8.77% | -11.43% | 20.53% | 19.94% | -11.15% | -8.68% | 35.25% | 24.37% |
| 2016 | -10.34% | -14.38% | -35.20% | -1.23% | 17.50% | 13.65% | -16.38% | -3.54% | -15.86% | -55.48% |
Risk-Adjusted Performance
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Aeglea BioTherapeutics, Inc. (AGLE) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Aeglea BioTherapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Aeglea BioTherapeutics, Inc. was 99.11%, occurring on Jun 21, 2023. The portfolio has not yet recovered.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.11% | Apr 11, 2016 | 1812 | Jun 21, 2023 | — | — | — |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Aeglea BioTherapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Aeglea BioTherapeutics, Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -1,011.9%.
Valuation
The Valuation section provides an overview of how Aeglea BioTherapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for AGLE compared to other companies in the Biotechnology industry. AGLE currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for AGLE relative to other companies in the Biotechnology industry. Currently, AGLE has a P/S ratio of 46.1. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for AGLE in comparison with other companies in the Biotechnology industry. Currently, AGLE has a P/B value of 0.4. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |